iBio, Inc.
NASDAQ:IBIOBiotechnology
Healthcare
$0.80 +0.00%
+$0.00 today
- Market cap
- $56.44M
- Beta
- 1.29
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.32
52W Low $0.78High $3.82
Volume 0.43M
Average 0.81M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$23.22M
FY 2026 · Annual
Investing Cash Flow
-$32.00M
FY 2026 · Annual
Financing Cash Flow
$103.05M
FY 2026 · Annual
+1054.1% YoYCash Flow Statement
USD
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Net Income | (29.51M) | (65.01M) | (24.91M) | (18.38M) | (33.04M) |
| Depreciation & Amortization | 3.79M | 1.38M | 1.25M | 291K | 88K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.38M | 4.39M | 2.04M | 1.53M | 1.37M |
| Change in Working Capital | 3.24M | 5.87M | (3.17M) | 479K | 2.52M |
| Accounts Receivables | 4.21M | 6.1M | 0 | 0 | (65K) |
| Inventory | (3.87M) | (1.02M) | 0 | 0 | 0 |
| Accounts Payables | 1.24M | (625K) | (1.49M) | 1.83M | 2.22M |
| Other Working Capital | 1.66M | 1.41M | (1.68M) | (1.35M) | 364K |
| Other Non-Cash Items | (15.32M) | 22.93M | 6.23M | 773K | 5.84M |
| Operating Cash Flow | (37.8M) | (30.44M) | (18.55M) | (15.3M) | (23.22M) |
| Capital Expenditures | (7.33M) | (5.74M) | (210K) | (16K) | (578K) |
| Acquisitions (Net) | 0 | (692K) | 0 | 0 | 0 |
| Purchases of Investments | (7.12M) | 0 | 0 | 0 | (42.3M) |
| Sales of Investments | 13.62M | 10.84M | 0 | 0 | 0 |
| Other Investing Activities | (4.3M) | 2.6M | 1.12M | 758K | 10.88M |
| Investing Cash Flow | (5.13M) | 7.01M | 906K | 742K | (32M) |
| Debt Repayment | (5.83M) | (9.13M) | (1.14M) | (771K) | (6.63M) |
| Common Stock Issued | 77K | 11.49M | 25.52M | 9.7M | 109.58M |
| Common Stock Repurchased | 0 | (39K) | (7K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (50K) | (22K) | 197K | 0 | 105K |
| Financing Cash Flow | (5.8M) | 2.3M | 24.49M | 8.93M | 103.05M |
| Effect of Forex Changes | (6M) | 33K | 0 | 0 | (18K) |
| Net Change in Cash | (54.73M) | (21.09M) | 6.85M | (5.63M) | 47.83M |
| Free Cash Flow | (45.13M) | (36.17M) | (18.76M) | (15.32M) | (23.8M) |
Free Cash Flow
Net Income to FCF bridge
FY2026
= Net Income-$33.0M
+ D&A$88.0K
+ Stock-Based Comp$1.4M
+ Deferred Tax$0
+ Working Capital$2.5M
+ Other Non-Cash$5.8M
= Operating Cash Flow-$23.2M
- Capex-$578.0K
= Free Cash Flow-$23.8M
Analysis
FY2026 free cash flow is -$23.8M. FCF conversion is 72.0% of net income. Operating cash flow was -$23.2M, with capex of -$578.0K. The largest bridge item is Other Non-Cash at $5.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Oct 19, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 15, 2026 |
Does IBIO generate free cash flow?
iBio, Inc. (IBIO) generated -$23.80M of free cash flow in fiscal 2026.
How much operating cash flow does IBIO produce?
Operating cash flow was -$23.22M, before capital expenditures of $578,000.00.
Continue the stock analysis
Jump to another research area for this company.